Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (6): 1071-1077. doi: 10.19723/j.issn.1671-167X.2019.06.017

Previous Articles     Next Articles

Diagnostic value of 18F-FDG PET/CT and tumor markers (CEA, CA19-9, CA24-2) in recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma

Xu-chu ZHANG,Jian-hua ZHANG,Rong-fu WANG(),Yan FAN,Zhan-li FU,Ping YAN,Guang-yu ZHAO,Yan-xia BAI   

  1. Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China
  • Received:2017-10-24 Online:2019-12-18 Published:2019-12-19
  • Contact: Rong-fu WANG E-mail:rongfu_wang@163.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To evaluate the diagnostic value of 18F-FDG PET/CT and tumor markers (CEA,CA19-9,CA24-2) in detection for recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma.Methods: Fifty-five patients were enrolled in this study. All of the patients were tested with serum CEA within 2 weeks when they underwent 18F-FDG PET/CT scan, and some patients were tested with serum CA19-9 and CA24-2 simultaneously. According to the pathology and clinical results of their follow-up, the sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET/CT and tumor markers were calculated based on different divided groups, respectively.Results: According to the pathology and the results of their clinical follow-up, the sensitivity of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 95.74%, 68.09%, 28.57%, 40.00% and 74.47%, respectively. The specificity of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 75.00%, 50.00%, 66.67%, 71.43% and 50.00%, respectively. The positive predictive value of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 95.74%, 88.89%, 85.71%, 88.89% and 89.74%, respectively. The negative predictive value of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 75.00%, 26.67%, 11.42%, 17.24%, 25.00%, respectively. The accuracy of 18F-FDG PET/CT, CEA, CA19-9, CA24-2 and the combination of those three tumor markers were 92.73%, 65.47%, 32.65%, 44.68% and 70.91%, respectively. There were 2 cases of false positive and 2 cases of false negative in 18F-FDG PET/CT.Conclusion: 18F-FDG PET/CT has high value in detecting recurrence and metastasis of postoperative colorectal carcinoma. Tumor markers have the positive value to imply the recurrence and metastasis of postoperative colorectal carcinoma and are useful to indicate when to perform the 18F-FDG PET/CT. The combination of tumor markers could improve the diagnostic efficiency to some extent.

Key words: Colorectal neoplasms, Positron emission tomography computed tomography, Biomarkers, tumor, Neoplasm recurrence, local, Neoplasm metastasis

CLC Number: 

  • R735.5

Table 1

The results of PET/CT, pathology and the group of tumor markers"

PET/CT Pathology CEA (n=55) CA19-9 (n=49) CA24-2 (n=47) Combination of tumor markers (n=55)
Elevated Normal Elevated Normal Elevated Normal Elevated Normal
Positive Positive 30 15 12 28 16 22 33 12
Positive Negative 1 1 1 1 1 1 1 1
Negative Negative 3 3 1 4 1 4 3 3
Negative Positive 2 0 0 2 0 2 2 0

Table 2

The efficiency of detection in PET/CT and tumor markers for recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma/%"

Testing items Sensitivity Specificity PPV NPV Accuracy
PET/CT (n=55) 95.74 75.00 95.74 75.00 92.73
CEA (n=55) 68.09 50.00 88.89 26.67 65.45
CA19-9 (n=49) 28.57 66.67 85.71 11.42 32.65
CA24-2 (n=47) 40.00 71.43 88.89 17.24 44.68
Combination of tumor markers (n=55) 74.47 50.00 89.74 25.00 70.91

Table 3

The efficiency of detection in PET/CT of tumor markers elevated group and normal group for recurrence and metastasis of postoperative colorectal moderately differentiated adenocarcinoma/%"

Group Sensitivity Specificity PPV NPV Accuracy
Elevated CEA (n=36) 93.75 75.00 96.77 60.00 91.67
Normal CEA (n=19) 100.00 75.00 93.75 100.00 94.74
Elevated CA19-9 (n=14) 100.00 50.00 92.31 100.00 92.86
Normal CA19-9 (n=35) 93.33 80.00 96.55 66.67 91.43
Elevated CA24-2 (n=18) 100.00 50.00 94.12 100.00 94.44
Normal CA24-2 (n=29) 91.67 80.00 95.56 66.67 89.66
Elevated tumor markers (n=39) 94.29 75.00 97.06 60.00 92.31
Normal tumor markers (n=16) 100.00 75.00 92.31 100.00 93.75

Figure 1

A patient of postoperation of rectum carcinoma, enlarged lymph node was showed near the right internal iliac artery, with normal tumor markers (CEA 1.86 μg/L, CA19-9 24.93 U/mL, CA24-2 18.13 U/mL) Marked 18F-FDG uptake on the enlarged lymph node near the right internal iliac artery."

Figure 2

A patient of postoperation of right colon carcinoma, cystic-solid lesion was found on the right annex region with considerate uptake of 18F-FDG, CEA 5.83 μg/L, CA19-9<0.60 U/mL, CA24-2 5.3 U/mL Marked 18F-FDG uptake on the right annex region was showed."

[1] 吴菲, 林国桢, 张晋昕 . 我国恶性肿瘤发病现状及趋势[J]. 中国肿瘤, 2012,21(2):81-85.
[2] 阮丽琴, 李太原, 周凤凤 . 不同年龄组的结直肠癌临床流行病学分析[J]. 实用临床医学, 2016,17(4):86-87.
[3] 张小龙, 高枫, 陈利生 , 等. 结直肠癌病理组织学类型分析[J]. 广西医学, 2008,30(11):1671-1672.
[4] 陈美玲 . 291例结直肠癌患者的临床病理分析[J]. 大家健康(学术版), 2015,9(8):66-67.
[5] 邱大胜, 胡晓燕, 彭辽河 , 等. 18F-FDG-PET/CT对结直肠癌术后血清CEA升高患者的诊断价值 [J]. 临床放射学杂志, 2013,32(12):1739-1742.
[6] 路晓雯, 刘林祥, 崔新建 , 等. 18F-FDG PET/CT对结直肠癌术后血清CEA升高病例的临床诊断价值 [J]. 泰山医学院学报, 2010,31(2):83-85.
[7] 潘睿. 中国慢性病前瞻性研究队列恶性肿瘤发病与死亡分析[C], 2017.
[8] 黄利娟, 陈继贵, 刘丽 , 等. 结直肠癌患者血清肿瘤标志物水平与预后关系[J]. 中国公共卫生, 2011,27(5):563-566.
doi: 10.11847/zgggws-2011-27-05-16
[9] Van Cutsem E, Cervantes A, Adam R , et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer[J]. Ann Oncol, 2016,27(8):1386-1422.
[10] 王贵玉 . 结直肠癌NCCN、NICE及ESMO指南的对比分析和解读[J]. 中国癌症杂志, 2015,25(11):849-853.
[11] Schmoll HJ, Van Cutsem E, Stein A , et al. ESMO Consensus Guidelines for management of patients with colon and rectal can-cer. A personalized approach to clinical decision making[J]. Ann Oncol, 2012,23(10):2479-2516.
[12] Chan K, Welch S, Walker-Dilks C , et al. Evidence-based guideline recommendations on the use of positron emission tomography imaging in colorectal cancer[J]. Clin Oncol (R Coll Radiol), 2012,24(4):232-249.
[13] 王晶晶, 陈康, 徐万菊 . 直肠癌患者手术前后血清CA199和CA242水平测定及预后评价[J]. 中华肿瘤防治杂志, 2009,14(21):1667-1668.
[14] 刘传, 清水汪, 王宁 , 等. 结直肠癌术前血清CEA、CA199表达水平与临床病理关系的研究[J]. 医学研究杂志, 2012,41(3):27-30.
[15] 周华胜, 梁光林 . 癌胚抗原测定在直肠癌手术前后及药物化疗过程中的追踪研究[J]. 河北医学, 2010,16(4):455-456.
[16] Lim YK, Kam MH, Eu KW . Carcinoembryonic antigen screening: how far should we go?[J]. Singapore Med J, 2009,50(9):862-865.
[17] 陈恺杰 . 3种血清肿瘤标志物在诊断大肠癌中的价值[J]. 广东医学院学报, 2005,23(4):384-385.
[18] 高志海, 田志军, 安燚 . 五种肿瘤标志物联合检测在胃和结直肠癌诊断及随访中的临床意义[J]. 医学综述, 2012,18(10):1595-1597.
[1] Zhaode BU, Mengyu FENG, Ke JI. Practice and reflection on sentinel lymph node navigation surgery for early gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 239-243.
[2] Hai WANG, Yizhou JIANG. Molecular mechanisms and clinical applications of anti-angiogenic therapy in precision treatment of breast cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 251-256.
[3] Bixian LUO, Hongming LIU, Weixun XIE, Weihua GONG. Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 257-265.
[4] Wen DU, Wenbo ZHANG, Yao YU, Shuo LIU, Huiyu SU, Leihao HU, Zunan TANG, Binzhang WU, Zhen CHEN, Jiaqi LI, Hao WANG, Xin PENG. Exploration and clinical application of the "digital and intelligent surgery" diagnosis and treatment workflow for oral and maxillofacial tumors [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 278-284.
[5] Haifeng DONG, Hengxing CHEN, Changhua ZHANG. Research progress on protein lactylation modification in malignant tumors [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 423-430.
[6] Ruofan GAO, Tianyu MA, Runkai WANG, Yuchen YIN, Ruidi LI, Dandan WANG, Bin XIA. Anti-inflammatory effects of cell membrane vesicle-mediated delivery of small interfering RNA targeting tumor necrosis factor-α on dental pulp stem cells [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 22-29.
[7] Zhao XIANG, Li YANG, Jing YANG. Untargeted metabolomics reveals differential serum metabolites and metabolic pathways in patients with primary Sjögren syndrome and thrombocytopenia [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1042-1050.
[8] Xiangyu SUN, Chao YUAN, Xinzhu ZHOU, Jing DIAO, Shuguo ZHENG. Application of salivary micro-ecosystem in early prevention and control of oral and systemic diseases [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 859-863.
[9] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[10] Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661.
[11] Qi MIAO, Baoan HONG, Xuezhou ZHANG, Zhipeng SUN, Wei WANG, Yuxuan WANG, Yuxuan BO, Jiahui ZHAO, Ning ZHANG. Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 698-703.
[12] Shuai LIU, Zhuo LIU, Yunhe GUAN, Guoliang WANG, Xiaojun TIAN, Hongxian ZHANG, Lei LIU, Lulin MA, Shudong ZHANG. Robot-assisted laparoscopic inferior vena cava segmental resection for renal tumor with tumor thrombus invading the vascular wall [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 796-802.
[13] Dan HAN, Yangjin CIREN, Qiuhong LI, Jun LI. Changes of intestinal microflora in patients with colorectal benign and malignant tumors in high altitude area and comparison with the normal population in low altitude area [J]. Journal of Peking University (Health Sciences), 2025, 57(3): 578-583.
[14] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
[15] Yuanyuan YANG, Shanshan ZHANG, Guangyan YU, Huijun YANG, Hongyu YANG. Clinical outcomes of partial sialoadenectomy for the treatment of benign tumors in the submandibular gland [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 334-339.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd